Meeting
2018 ASCO Annual Meeting
KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
Presenter
Johann S. De Bono, MD, PhD, FRCP
Royal Marsden Hospital
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02787005
Citation
J Clin Oncol 36, 2018 (suppl; abstr 5007)
DOI
10.1200/JCO.2018.36.15_suppl.5007
Abstract #
5007
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2020 ASCO Virtual Scientific Program
KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).
Speaker: Christopher J. Hoimes, DO
Videos & Slides
2020 ASCO Virtual Scientific Program
Biomarker analysis from the KEYNOTE-199 trial of pembrolizumab in patients (pts) with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
Speaker: Emmanuel S. Antonarakis, MD
Videos & Slides
2020 Genitourinary Cancers Symposium
Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5.
Speaker: Julie N Graff, MD
Videos & Slides
2023 ASCO Genitourinary Cancers Symposium
First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: Phase 2a final results.
Speaker: Rahul Raj Aggarwal, MD